Report Sections

See All Reports

Coronavirus Infections (840) Severe Acute Respiratory Syndrome (575) Infection (491) Pneumonia (381) Communicable Diseases (217) Respiratory Distress Syndrome, Adult (187) Acute Lung Injury (148) Respiratory Distress Syndrome, Newborn (148) (134) Syndrome (129) Virus Diseases (98) Depression (92) Pneumonia, Viral (81) Critical Illness (69) Anxiety Disorders (57) Neoplasms (47) Respiratory Tract Infections (46) Disease (41) Diabetes Mellitus (39) Cardiovascular Diseases (38) Stress Disorders, Post-Traumatic (38) Emergencies (36) Wounds and Injuries (36) Depressive Disorder (35) Inflammation (35) Lung Diseases (33) Stress Disorders, Traumatic (33) Stress, Psychological (33) Respiratory Tract Diseases (31) Hypoxia (30) Lung Injury (30) Acute Kidney Injury (29) Mental Disorders (29) Thrombosis (29) Influenza, Human (27) Hypertension (25) Respiration Disorders (23) Disease Progression (22) Fibrosis (22) Cognitive Dysfunction (21) Olfaction Disorders (21) Arthritis (20) Diabetes Mellitus, Type 2 (20) Sclerosis (20) Burnout, Psychological (19) Multiple Sclerosis (19) Pulmonary Disease, Chronic Obstructive (19) Respiratory Aspiration (19) Thromboembolism (19) Embolism (18) Lung Diseases, Obstructive (18) Pulmonary Fibrosis (18) HIV Infections (17) Kidney Diseases (17) Stroke (17) Blood Coagulation Disorders (16) Heart Failure (16) Hemostatic Disorders (16) Pulmonary Embolism (16) Arthritis, Rheumatoid (15) Asthma (15) Chronic Disease (15) Heart Diseases (15) Lung Diseases, Interstitial (15) Lung Neoplasms (15) Myocardial Infarction (15) Substance-Related Disorders (15) Autism Spectrum Disorder (14) Chronic Pain (14) Crohn Disease (14) Brain Injuries (13) Diabetes Mellitus, Type 1 (13) Infarction (13) Venous Thrombosis (12) Autistic Disorder (11) Carcinoma (11) Colitis (11) Colitis, Ulcerative (11) Dyspnea (11) Feeding and Eating Disorders (11) Obesity (11) Rheumatic Diseases (11) Ulcer (11) Alzheimer Disease (10) Burnout, Professional (10) Leukemia (10) Lymphoma (10) Myocarditis (10) Overweight (10) Parkinson Disease (10) Pregnancy Complications (10) Renal Insufficiency, Chronic (10) Respiratory Syncytial Virus Infections (10) Sepsis (10) Brain Injuries, Traumatic (9) Collagen Diseases (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Dementia (9) Depression, Postpartum (9) Frailty (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Musculoskeletal Pain (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Weight Loss (9) Alcohol Drinking (8) Alcoholism (8) Hematologic Neoplasms (8) Infertility (8) Ischemia (8) Parasomnias (8) Problem Behavior (8) Psychotic Disorders (8) RNA Virus Infections (8) Breast Neoplasms (7) Convalescence (7) Coronary Disease (7) Dyssomnias (7) Fatigue (7) Metabolic Syndrome (7) Migraine Disorders (7) Myocardial Ischemia (7) Neoplasm Metastasis (7) Psoriasis (7) Schizophrenia (7) Shock (7) Spinal Cord Injuries (7) Toxemia (7) Acute Coronary Syndrome (6) Brain Diseases (6) Bronchiectasis (6) Carcinoma, Non-Small-Cell Lung (6) Child Development Disorders, Pervasive (6) Colorectal Neoplasms (6) Deglutition Disorders (6) Delirium (6) Disease Susceptibility (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Kidney Failure, Chronic (6) Lupus Erythematosus, Systemic (6) Lymphopenia (6) Multiple Organ Failure (6) Neurologic Manifestations (6) Osteoarthritis (6) (6) Pediatric Obesity (6) Prostatic Neoplasms (6) Sleep Apnea Syndromes (6) Sleep Apnea, Obstructive (6) Appendicitis (5) Arthritis, Psoriatic (5) Autoimmune Diseases (5) Coronaviridae Infections (5) Cross Infection (5) Depressive Disorder, Major (5) Dermatitis (5) Disseminated Intravascular Coagulation (5) Fibromyalgia (5) Gastroparesis (5) Head and Neck Neoplasms (5) Hypersensitivity (5) Idiopathic Pulmonary Fibrosis (5) Leukemia, Lymphoid (5) Metabolic Diseases (5) Mobility Limitation (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) Pancreatic Neoplasms (5) Premature Birth (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Acute Disease (4) Adenoviridae Infections (4) Amyotrophic Lateral Sclerosis (4) Anemia, Sickle Cell (4) Arrhythmias, Cardiac (4) Asymptomatic Diseases (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Carcinoma, Renal Cell (4) Cognition Disorders (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Dermatitis, Atopic (4) Digestive System Diseases (4) Eczema (4) Embolism and Thrombosis (4) Endometriosis (4) Gastrointestinal Diseases (4) Headache (4) Heart Arrest (4) Hematologic Diseases (4) Hemophilia A (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Macular Degeneration (4) Malnutrition (4) Motor Neuron Disease (4) (4) Mycobacterium Infections (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Spondylarthritis (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Apnea (3) Bacteremia (3) Bacterial Infections (3) Bulimia (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Congenital Abnormalities (3) Developmental Disabilities (3) Dysgeusia (3) Endocrine System Diseases (3) Eye Diseases (3) Fatigue Syndrome, Chronic (3) Fatty Liver (3) Fever (3) Fistula (3) Fractures, Bone (3) Ganglion Cysts (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Heart Defects, Congenital (3) Hepatitis C (3) Huntington Disease (3) Hyperglycemia (3) Hypothermia (3) Kidney Calculi (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Leukemia, Myeloid, Acute (3) Macular Edema (3) Measles (3) Melanoma (3) Meningitis (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Myeloma (3) Multiple Sclerosis, Relapsing-Remitting (3) Myelodysplastic Syndromes (3) Myeloproliferative Disorders (3) Neoplasms, Plasma Cell (3) Neuroendocrine Tumors (3) Non-alcoholic Fatty Liver Disease (3) Obesity, Morbid (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Nervous System Diseases (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Shock, Septic (3) Sleep Wake Disorders (3) Small Cell Lung Carcinoma (3) Suicidal Ideation (3) Tachycardia (3) Taste Disorders (3) Tuberculosis (3) Ageusia (2) Agoraphobia (2) Alcoholic Intoxication (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Aortic Valve Stenosis (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrophy (2) Back Pain (2) Behcet Syndrome (2) Binge-Eating Disorder (2) Bipolar Disorder (2) Bronchitis (2) Bronchitis, Chronic (2) Bronchopulmonary Dysplasia (2) Caliciviridae Infections (2) Carcinoma, Small Cell (2) Carcinoma, Squamous Cell (2) Cataract (2) Cholangitis (2) Clinical Deterioration (2) Clostridium Infections (2) Communicable Diseases, Emerging (2) Communication Disorders (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Conjunctivitis (2) Depressive Disorder, Treatment-Resistant (2) Diabetic Nephropathies (2) Diabetic Neuropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Epilepsy (2) Facies (2) Fractures, Stress (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Genetic Predisposition to Disease (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hepatitis (2) Hepatitis A (2) Humeral Fractures (2) Hyperkinesis (2) Hyperphagia (2) Hyperplasia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Infertility, Male (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid (2) Low Back Pain (2) Lymphedema (2) Lymphoma, B-Cell (2) Lymphoma, Mantle-Cell (2) Lymphoproliferative Disorders (2) Meningitis, Meningococcal (2) Mood Disorders (2) Mucositis (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Nephrolithiasis (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Oropharyngeal Neoplasms (2) Pain (2) Pain, Postoperative (2) Pancreatitis (2) Paresis (2) Periodontal Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Bacterial (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Preleukemia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Spinal Diseases (2) Sprains and Strains (2) Squamous Cell Carcinoma of Head and Neck (2) Stillbirth (2) Stomatitis (2) Suicide (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Thyroid Diseases (2) Trauma and Stressor Related Disorders (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Wet Macular Degeneration (2) Yellow Fever (2) Abortion, Spontaneous (1) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Aggression (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia (1) Anemia, Aplastic (1) Anemia, Iron-Deficiency (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Ankle Fractures (1) Anorexia (1) Anorexia Nervosa (1) Arachnoiditis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Brain Neoplasms (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Brucellosis (1) Bruxism (1) Bulimia Nervosa (1) (1) Calculi (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Carcinoma, Ovarian Epithelial (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colitis, Ulcerativ (1) Colonic Diseases (1) (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Coronavirus Infect (1) Cough (1) Coxsackievirus Infections (1) Crohn Dise (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) DiGeorge Syndrome (1) Diabetic Foot (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dry Eye Syndromes (1) Dysentery, Bacillary (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epstein-Barr Virus Infections (1) Escherichia coli Infections (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gambling (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Geographic Atrophy (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Glomerulonephritis, Membranous (1) Guillain-Barre Syndrome (1) Halitosis (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hot Flashes (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperkalemia (1) Hyperphosphatemia (1) Hypersensitivity, Immediate (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infectious Mononucleosis (1) Infertility, Female (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratoconjunctivitis Sicca (1) Keratosis (1) Keratosis, Actinic (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Leukemia, Prolymphocytic (1) Leukemia, Prolymphocytic, T-Cell (1) Lichen Sclerosus et Atrophicus (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Lung Ne (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Meningomyelocele (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myelodysplastic-Myeloproliferative Diseases (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplasms, Germ Cell and Embryonal (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Oligospermia (1) Opioid-Related Disorders (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Parkin (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Pocket (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Polyps (1) Pregnancy in Diabetics (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Heart Disease (1) Rabies (1) Radiculopathy (1) Rectal Fistula (1) Rectal Neoplasms (1) Reperfusion Injury (1) Resp (1) Respiratory Distre (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Restless Legs Syndrome (1) Retinal Vein Occlusion (1) Rhinitis (1) Rhinitis, Allergic (1) Rhinitis, Allergic, Seasonal (1) Sarcoma (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Shoulder Fractures (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Speech Sound Disorder (1) Spina Bifida Cystica (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylitis (1) Spondylitis, Ankylosing (1) Spondylolisthesis (1) Status Epilepticus (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Synovial Cyst (1) Tachycardia, Sinus (1) Tachycardia, Supraventricular (1) Tachycardia, Ventricular (1) Tachypnea (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tissue Adhesions (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Meningeal (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Lichen Sclerosus (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D003093: Colitis, Ulcerativ

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (35)


Name (Synonyms) Correlation
drug5134 placebo for risankizumab Wiki 0.33
drug1344 Discontinuation of anti-TNF treatment Wiki 0.29
drug2258 JNJ-66525433 Wiki 0.29
Name (Synonyms) Correlation
drug1417 ELISPOT Wiki 0.29
drug3153 Personalized ambulatory training Wiki 0.29
drug1443 Eating habits Wiki 0.29
drug4581 Upadacitinib (ABT-494) Wiki 0.29
drug1372 Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment Wiki 0.29
drug1110 Continuation of anti-TNF treatment Wiki 0.29
drug1376 Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) Wiki 0.29
drug2972 Ontamalimab Wiki 0.29
drug1440 Early rehabilitation Wiki 0.29
drug3200 Placebo (PB0) Wiki 0.29
drug2312 Late-Dexamethasone Wiki 0.29
drug1415 ELISA Wiki 0.29
drug1217 Cytochrome P450 (CYP) Substrates Wiki 0.29
drug5195 risankizumab Wiki 0.29
drug1377 Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole Wiki 0.29
drug4174 Subacute rehabilitation Wiki 0.29
drug3469 QUANTIFERON Wiki 0.29
drug1416 ELISA and Rapid test to detect antibodies against COVID-19 Wiki 0.29
drug2227 Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment Wiki 0.29
drug2636 Mindfulness training Wiki 0.29
drug3704 Risankizumab Wiki 0.20
drug3140 Peripheral blood draw Wiki 0.20
drug1441 Early-Dexamethasone Wiki 0.20
drug1737 GLPG3970 Wiki 0.20
drug1395 Duvelisib Wiki 0.20
drug3551 RT-PCR Wiki 0.17
drug5196 risankizumab IV Wiki 0.17
drug1413 EIDD-2801 Wiki 0.17
drug1446 Echocardiography Wiki 0.17
drug5197 risankizumab SC Wiki 0.17
drug4138 Standard treatment Wiki 0.11
drug3195 Placebo Wiki 0.06

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D003092 Colitis NIH 0.96
D014456 Ulcer NIH 0.78
D009336 Necrosis NIH 0.20
Name (Synonyms) Correlation
D015212 Inflammatory Bowel Diseases NIH 0.19
D003424 Crohn Disease NIH 0.15
D007410 Intestinal Diseases NIH 0.14

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0002583 Colitis HPO 0.96
HP:0100279 Ulcerative colitis HPO 0.92
HP:0002037 Inflammation of the large intestine HPO 0.19
Name (Synonyms) Correlation
HP:0100280 Crohn's disease HPO 0.15
HP:0002242 Abnormal intestine morphology HPO 0.14

Clinical Trials

Navigate: Correlations   HPO

There are 12 clinical trials


1 A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)

The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of participant-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

NCT03259334
Conditions
  1. Ulcerative Colitis
Interventions
  1. Drug: Ontamalimab
  2. Other: Placebo
MeSH:Colitis Colitis, Ulcerativ Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Remission is defined as a composite score of participant-reported symptoms using daily e-diary and centrally read endoscopy as stool frequency subscore of 0 or 1 with at least a 1-point change from baseline, rectal bleeding subscore of 0 and endoscopic subscore of 0 or 1 (modified, excludes friability). The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); Physician global assessment (PGA: 0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Remission at Week 12

Time: Week 12

Secondary Outcomes

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Endoscopic Remission at Week 12

Time: Week 12

Description: Clinical remission is defined by stool frequency subscore of 0 or 1 with at least a 1-point change from baseline in stool frequency subscore, and rectal bleeding subscore of 0. The stool frequency subscore and rectal bleeding subscore range from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Clinical Remission at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Clinical response (composite) is defined as a decrease from baseline in the composite score of participant-reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding greater than or equal to (>=) 1 point or a subscore for rectal bleeding less than or equal to (<=) 1. The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Response (Composite) at Week 12

Time: Week 12

Description: Mucosal healing is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability) and centrally read Geboes score of <=2. The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Mucosal Healing at Week 12

Time: Week 12

Description: Remission is defined as a total mayo score of less than or equal to <=2 with no individual subscore (stool frequency, rectal bleeding, endoscopy [modified, excludes friability], and physician's global assessment) exceeding 1, at the Week 12. The total mayo score ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Remission Based on Total Mayo Score at Week 12

Time: Week 12

Description: Clinical response (Mayo) is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding >=1 point or an absolute subscore for rectal bleeding <=1. The total mayo score ranges from 0 to 12 points and consists of the following 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Clinical Response Based on Total Mayo Score at Week 12

Time: Week 12

Description: The partial mayo score ranges from 0 to 9 points and consists of the following 3 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); PGA (0-3). The partial Mayo score does not include the endoscopy subscore. Number of participants with partial mayo score <=2 with no individual subscore >1 at the Week 4, 8, 12 will be assessed.

Measure: Number of Participants With Partial Mayo Score Less than or Equal (<=) 2 with no individual subscore Greater than (>) 1 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Here number of participants with endoscopic remission at week 12 with a subscore of 0 will be assessed.

Measure: Number of Participants with Endoscopic Remission at Week 12 With Endoscopic Subscore of 0

Time: Week 12

Description: Clinical remission with both rectal bleeding and stool frequency subscores of 0 at week 4, 8, 12 will be assessed. The stool frequency subscore and rectal bleeding subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Remission With Both Rectal Bleeding and Stool Frequency Subscores of 0 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Deep remission is defined as both endoscopic and rectal bleeding subscores of 0, and stool frequency subscore <=1 and a centrally read Geboes score of <=2.. The stool frequency subscore, rectal bleeding subscore and endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Deep Remission at Week 12

Time: Week 12

Description: Participants will be asked to record the abdominal pain worst severity using 0-10 numeric rating scale, with 0 anchor at "No pain" and 10 at "Worst Imaginable Pain" as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Abdominal Pain Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the diarrhea frequency (enter number of loose or watery bowel movements) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Diarrhea Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the urgency frequency (enter number of bowel movements with urgency) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Urgency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the stool frequency (enter number of bowel movements passed) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Stool Frequency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the rectal bleeding severity and frequency (enter number of bowel movements with blood) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Rectal Bleeding Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The total sign/symptom score (average of rectal bleeding, stool frequency, abdominal pain, diarrhea, and urgency) ranges from 0 to 10 with higher scores indicating higher severity.

Measure: Change From Baseline Total Sign/Symptom Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The IBDQ is a psychometrically validated participant-reported outcome (PRO) instrument for measuring the disease-specific HRQL in participants with inflammatory bowel disease, including UC. The IBDQ consists of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better HRQL. A score of at least 170 corresponds to clinical remission and an increase of at least 16 points is considered to indicate a clinically meaningful improvement.

Measure: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domains and Total Absolute Scores in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 8, 12

Time: Baseline, Week 8, 12

Description: The SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQL) of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQL.

Measure: Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores and Individual Domain Scores) at Week 12

Time: Baseline, Week 12

Description: Incidence of hospitalizations during the entire study period will be assessed.

Measure: Incidence of Hospitalizations

Time: From start of study up to follow up (Week 29)

Description: Incidence of total inpatient days during the entire study period will be assessed.

Measure: Incidence of Total Inpatient Days

Time: From start of study up to follow up (Week 29)
2 A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have successfully completed Study M14-234 Substudy 3.

NCT03006068
Conditions
  1. Ulcerative Colitis (UC)
Interventions
  1. Drug: Upadacitinib (ABT-494)
  2. Drug: Placebo
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Treatment-emergent adverse events are defined as events that begin or worsen either on or after the first dose of the study drug and within 30 days after the last dose of the study drug in the analysis period.

Measure: Assessing Treatment-Emergent Adverse Events

Time: Up to 288 Weeks
3 Continuing or Discontinuing Anti-tumor Necrosis Factor Treatment in Patients With Ulcerative Colitis in Clinical Remission: a Prospective Open Randomized Parallel-group Study

The primary objective is to assess if discontinuation of anti- tumor necrosis factor alpha (TNF) treatment in ulcerative colitis patients in sustained clinical remission, with the option to restart treatment in the case of relapse, is non-inferior to continued anti-TNF treatment. Secondary objectives are to assess the efficacy and safety of restarting anti-TNF treatment after a relapse

NCT03011268
Conditions
  1. Colitis,Ulcerative
Interventions
  1. Other: Discontinuation of anti-TNF treatment
  2. Other: Continuation of anti-TNF treatment
MeSH:Colitis Colitis, Ulcerative Ulcer Necrosis
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 2 years of randomized treatment

Measure: Proportion of patients in sustained clinical remission

Time: 2 years

Secondary Outcomes

Description: Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 4 years of randomized treatment

Measure: Proportion of patients in sustained clinical remission

Time: 4 years

Description: Relapse time

Measure: Time from randomization to relapse

Time: 2 years

Description: Relapse time

Measure: Time from randomization to relapse

Time: 4 years

Description: Remission, but no need to restart anti-tnf therapy

Measure: Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy

Time: 2 years

Description: Remission, but no need to restart anti-tnf therapy

Measure: Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy

Time: 4 years

Description: Remission after relapse

Measure: Proportion of relapse patients achieving remission after anti-TNF restart

Time: 2 years

Description: Remission after relapse

Measure: Proportion of relapse patients achieving remission after anti-TNF restart

Time: 4 years

Description: Adverse events

Measure: Adverse events and serious adverse events frequency and severity

Time: 2 years

Description: Adverse events

Measure: Adverse events and serious adverse events frequency and severity

Time: 4 years
4 A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

NCT03259308
Conditions
  1. Ulcerative Colitis
Interventions
  1. Drug: Ontamalimab
  2. Drug: Placebo
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Remission is defined as a composite score of patient-reported symptoms using daily ediary and centrally read endoscopy as stool frequency subscore of 0 or 1 with at least a 1-point change from baseline, rectal bleeding subscore of 0 and endoscopic subscore of 0 or 1 (modified, excludes friability). The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); Physician global assessment (PGA: 0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Remission at Week 12

Time: Week 12

Secondary Outcomes

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Endoscopic Remission at Week 12

Time: Week 12

Description: Clinical remission is defined by stool frequency subscore of 0 or 1 with at least a 1-point change from baseline in stool frequency subscore, and rectal bleeding subscore of 0. The stool frequency subscore and rectal bleeding subscore range from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Clinical Remission at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Clinical response (composite) is defined as a decrease from baseline in the composite score of patient-reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding greater than or equal to (>=) 1 point or a subscore for rectal bleeding less than or equal to (<=) 1. The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Response (Composite) at Week 12

Time: Week 12

Description: Mucosal healing is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability) and centrally read Geboes score of <=2. The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Mucosal Healing at Week 12

Time: Week 12

Description: Remission is defined as a total mayo score of less than or equal to <=2 with no individual subscore (stool frequency, rectal bleeding, endoscopy [modified, excludes friability], and PGA) exceeding 1, at the Week 12. The total mayo score ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Remission Based on Total Mayo Score at Week 12

Time: Week 12

Description: Clinical response (Mayo) is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding >=1 point or an absolute subscore for rectal bleeding <=1. The total mayo score ranges from 0 to 12 points and consists of the following 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Clinical Response Based on Total Mayo Score at Week 12

Time: Week 12

Description: The partial mayo score ranges from 0 to 9 points and consists of the following 3 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); PGA (0-3). The partial Mayo score does not include the endoscopy subscore. Here participants with partial Mayo score <= 2 with no individual subscore >1 at the Week 4, 8, and 12 will be assessed.

Measure: Number of Participants With Partial Mayo Score Less than or Equal to (<=) 2 with no Individual Subscore Greater than (>) 1 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Here number of participants with endoscopic remission at week 12 with a subscore of 0 will be assessed.

Measure: Number of Participants with Endoscopic Remission at Week 12 With Endoscopic Subscore of 0

Time: Week 12

Description: Clinical remission with both rectal bleeding and stool frequency subscores of 0 at week 4, 8, 12 will be assessed. The stool frequency subscore and rectal bleeding subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Remission With Both Rectal Bleeding and Stool Frequency Subscores of 0 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Deep remission is defined as both endoscopic and rectal bleeding subscores of 0, and stool frequency subscore <=1 and a centrally read Geboes score of <=2.. The stool frequency subscore, rectal bleeding subscore and endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Deep Remission at Week 12

Time: Week 12

Description: Participants will be asked to record the abdominal pain worst severity using 0-10 numeric rating scale, with 0 anchor at "No pain" and 10 at "Worst Imaginable Pain" as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Abdominal Pain Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the diarrhea frequency (enter number of loose or watery bowel movements) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Diarrhea Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the urgency frequency (enter number of bowel movements with urgency) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Urgency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the stool frequency (enter number of bowel movements passed) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Stool Frequency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the rectal bleeding severity and frequency (enter number of bowel movements with blood) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Rectal Bleeding Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The total sign/symptom score (average of rectal bleeding, stool frequency, abdominal pain, diarrhea, and urgency) ranges from 0 to 10 with higher scores indicating higher severity.

Measure: Change From Baseline Total Sign/Symptom Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The IBDQ is a psychometrically validated participant-reported outcome (PRO) instrument for measuring the disease-specific HRQL in participants with inflammatory bowel disease, including UC. The IBDQ consists of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better HRQL. A score of at least 170 corresponds to clinical remission and an increase of at least 16 points is considered to indicate a clinically meaningful improvement.

Measure: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domains and Total Absolute Scores in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 8, 12

Time: Baseline, Week 8, 12

Description: The SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQL) of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQL.

Measure: Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores and Individual Domain Scores) at Week 12

Time: Baseline, Week 12

Description: Incidence of hospitalizations during the entire study period will be assessed.

Measure: Incidence of Hospitalizations

Time: From start of study up to follow up (Week 29)

Description: Incidence of total inpatient days during the entire study period will be assessed.

Measure: Incidence of Total Inpatient Days

Time: From start of study up to follow up (Week 29)
5 A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)

The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of participant-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis (UC).

NCT03259334
Conditions
  1. Ulcerative Colitis
Interventions
  1. Drug: Ontamalimab
  2. Other: Placebo
MeSH:Colitis Colitis, Ulcerativ Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Remission is defined as a composite score of participant-reported symptoms using daily e-diary and centrally read endoscopy as stool frequency subscore of 0 or 1 with at least a 1-point change from baseline, rectal bleeding subscore of 0 and endoscopic subscore of 0 or 1 (modified, excludes friability). The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); Physician global assessment (PGA: 0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Remission at Week 12

Time: Week 12

Secondary Outcomes

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Endoscopic Remission at Week 12

Time: Week 12

Description: Clinical remission is defined by stool frequency subscore of 0 or 1 with at least a 1-point change from baseline in stool frequency subscore, and rectal bleeding subscore of 0. The stool frequency subscore and rectal bleeding subscore range from 0 to 3 with higher scores indicating more severe disease.

Measure: Number of Participants With Clinical Remission at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Clinical response (composite) is defined as a decrease from baseline in the composite score of participant-reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding greater than or equal to (>=) 1 point or a subscore for rectal bleeding less than or equal to (<=) 1. The Mayo score is a measure of UC disease activity. It ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease The subscores are Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3). The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Response (Composite) at Week 12

Time: Week 12

Description: Mucosal healing is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability) and centrally read Geboes score of <=2. The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Mucosal Healing at Week 12

Time: Week 12

Description: Remission is defined as a total mayo score of less than or equal to <=2 with no individual subscore (stool frequency, rectal bleeding, endoscopy [modified, excludes friability], and physician's global assessment) exceeding 1, at the Week 12. The total mayo score ranges from 0 to 12 points and consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Remission Based on Total Mayo Score at Week 12

Time: Week 12

Description: Clinical response (Mayo) is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding >=1 point or an absolute subscore for rectal bleeding <=1. The total mayo score ranges from 0 to 12 points and consists of the following 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); Findings of endoscopy (0-3); PGA (0-3).

Measure: Number of Participants With Clinical Response Based on Total Mayo Score at Week 12

Time: Week 12

Description: The partial mayo score ranges from 0 to 9 points and consists of the following 3 subscores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); PGA (0-3). The partial Mayo score does not include the endoscopy subscore. Number of participants with partial mayo score <=2 with no individual subscore >1 at the Week 4, 8, 12 will be assessed.

Measure: Number of Participants With Partial Mayo Score Less than or Equal (<=) 2 with no individual subscore Greater than (>) 1 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Endoscopic remission is defined by centrally read endoscopic subscore 0 or 1 (modified, excludes friability). The centrally read endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. Here number of participants with endoscopic remission at week 12 with a subscore of 0 will be assessed.

Measure: Number of Participants with Endoscopic Remission at Week 12 With Endoscopic Subscore of 0

Time: Week 12

Description: Clinical remission with both rectal bleeding and stool frequency subscores of 0 at week 4, 8, 12 will be assessed. The stool frequency subscore and rectal bleeding subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points.

Measure: Number of Participants With Clinical Remission With Both Rectal Bleeding and Stool Frequency Subscores of 0 at Week 4, 8, 12

Time: Week 4, 8, 12

Description: Deep remission is defined as both endoscopic and rectal bleeding subscores of 0, and stool frequency subscore <=1 and a centrally read Geboes score of <=2.. The stool frequency subscore, rectal bleeding subscore and endoscopic subscore of mayo score ranges from 0 to 3 with higher scores indicating more severe disease. The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points. Geboes score grading system, is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher geboes score indicates more severe disease.

Measure: Number of Participants With Deep Remission at Week 12

Time: Week 12

Description: Participants will be asked to record the abdominal pain worst severity using 0-10 numeric rating scale, with 0 anchor at "No pain" and 10 at "Worst Imaginable Pain" as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Abdominal Pain Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the diarrhea frequency (enter number of loose or watery bowel movements) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Diarrhea Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the urgency frequency (enter number of bowel movements with urgency) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Urgency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the stool frequency (enter number of bowel movements passed) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Stool Frequency Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: Participants will be asked to record the rectal bleeding severity and frequency (enter number of bowel movements with blood) as experienced over the previous 24 hours, in the e-diary.

Measure: Change From Baseline in Absolute Rectal Bleeding Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The total sign/symptom score (average of rectal bleeding, stool frequency, abdominal pain, diarrhea, and urgency) ranges from 0 to 10 with higher scores indicating higher severity.

Measure: Change From Baseline Total Sign/Symptom Score Based on Participant e-Diary at Week 12

Time: Baseline, Week 12

Description: The IBDQ is a psychometrically validated participant-reported outcome (PRO) instrument for measuring the disease-specific HRQL in participants with inflammatory bowel disease, including UC. The IBDQ consists of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better HRQL. A score of at least 170 corresponds to clinical remission and an increase of at least 16 points is considered to indicate a clinically meaningful improvement.

Measure: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domains and Total Absolute Scores in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 8, 12

Time: Baseline, Week 8, 12

Description: The SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQL) of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role - physical, bodily pain, general health, vitality, social functioning, role - emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQL.

Measure: Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores and Individual Domain Scores) at Week 12

Time: Baseline, Week 12

Description: Incidence of hospitalizations during the entire study period will be assessed.

Measure: Incidence of Hospitalizations

Time: From start of study up to follow up (Week 29)

Description: Incidence of total inpatient days during the entire study period will be assessed.

Measure: Incidence of Total Inpatient Days

Time: From start of study up to follow up (Week 29)
6 Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease

Breastfeeding is beneficial to both mother and baby. However, many breastfeeding women are affected by long-term health conditions and need to take medications. Sometimes, concerns about transfer of drugs to infants via breast milk lead the mothers to either avoid breastfeeding or stop their medication. Inflammatory Bowel Disease (IBD) is a chronic condition that is marked by an abnormal response of the body's immune system, and high levels of certain proteins that cause inflammation (Cytokines like Tumor Necrosis Factor-alpha or TNFα). A group of drugs called "biologics" target and stop these proteins from causing inflammation, and have been successfully used to treat this condition. Inflammatory proteins may be present in breast milk of healthy women in variable levels, and may play a role in development of infant's brain and immune system. This study is being conducted to investigate: - Concentration of some of the inflammatory proteins in breast milk of mothers with IBD and healthy controls - Interaction between these proteins and biologics in breast milk of women with IBD - Potential role of these proteins (and their interaction with biologics) on development of infant learning and memory function It has been presumed that concentrations of TNFα and some other cytokines are higher in breast milk of women with IBD, and the biologics can normalize these high levels. Due to precautions for COVID-19, the study now consists of only two mandatory study visits and two optional study visits. The mandatory visits include two home visits in the first 4 months postpartum to complete a participant questionnaire and collect a small sample of breast milk at each visit. The optional study visits consist of two visits at the Hospital for Sick Children for evaluation of learning and memory function of the infant at the ages of 12 and 18 months. Additionally, mothers will be required to complete for their infant subscales of The Ages and Stages Questionnaires®, Third Edition (ASQ®-3) either in person or over the telephone at the ages of 12 months and 18 months.

NCT03397108
Conditions
  1. Crohn's Disease
  2. Ulcerative Colitis
  3. Healthy Controls
MeSH:Crohn Disease Colitis Colitis, Ulcerative Intestinal Diseases Inflammatory Bowel Diseases
HPO:Abnormal intestine morphology Colitis Crohn's disease Inflammation of the large intestine Ulcerative colitis

Primary Outcomes

Description: Multiplex assay will be used to measure TNFα and downstream chemokines including CCL2, CCL4, CCL7, CXCL10 in breast milk of two groups of participants (women with IBD and healthy controls). (The unit of measurement is the same for all these cytokines)

Measure: Levels of TNFα and its downstream chemokines (CCL2, CCL4, CCL7, and CXCL10) in breast milk of women with IBD and healthy controls by Multiplex assay

Time: 4 years

Secondary Outcomes

Description: ELISA assay will be used to measure total and free drug levels (bound and unbound to TNFα) in breast milk of lactating women with IBD. (The unit of measurement is the same for infliximab and adalimumab).

Measure: Milk concentration of TNFα inhibitors (infliximab, adalimumab) at different time-points between two doses of medication, in lactating women with IBD by ELISA assay

Time: 4 years

Description: The infants of women with IBD and healthy controls will be examined for cognitive development using Bayley-III

Measure: Scores on cognitive subset of Bayley Scales of Infant and Toddler development- Third Version (Bayley-III) in infants of healthy controls and women with IBD

Time: 4 years

Description: Infants of healthy controls and women with IBD will be examined for communication and problem-solving development using the ASQ®-3. This supplementary measure is intended to provide additional data as an alternative to Bayley test under unprecedented circumstances which preclude participants to complete Bayley test at the Hospital for Sick Children

Measure: Scores on the "Problem-solving" and "Communication" subscales of The Ages and Stages Questionnaire (ASQ®-3) in infants of healthy controls and women with IBD

Time: 4 years

Description: An estimation of the population distribution of anti-TNFα antibodies (infliximab and adalimumab) in breast milk of women with IBD will be made, using population pharmacokinetic modelling

Measure: Simulated/predicted profiles of TNFα inhibitors (infliximab, adalimumab) in breast milk in a large population of lactating women with IBD by population pharmacokinetic modelling

Time: 4 years
7 A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. This study consists of three sub-studies: Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic.

NCT03398135
Conditions
  1. Ulcerative Colitis (UC)
Interventions
  1. Drug: risankizumab
  2. Drug: placebo for risankizumab
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score

Time: Week 52

Description: An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Measure: Sub-Study 3: Percentage of Participants with Adverse Events (AE)

Time: Up to Week 300

Secondary Outcomes

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Improvement

Time: Week 52

Description: Clinical remission per full Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Remission per Full Mayo Score in Participants with a Full Mayo Score of 6 to 12 at Baseline (of Induction)

Time: Week 52

Description: Percentage of participants who discontinued corticosteroid use, in participants taking steroids at baseline (of induction).

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use, in Participants Taking Steroids at Baseline (of induction).

Time: Week 52

Description: Clinical remission per Adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with a Clinical Remission at Week 0

Time: Week 52

Description: Participants who discontinued corticosteroid use.

Measure: Sub-Study 1: Percentage of Participants who Discontinued Corticosteroid Use, Remained Corticosteroid Free for 90 days and Achieved Clinical Remission in Participants who were Taking Steroids at Baseline (of induction)

Time: Week 52

Description: Clinical response per Adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants with Clinical Response per Adapted Mayo Score

Time: Week 52

Description: Percentage of participants achieving histologic-endoscopic mucosal improvement.

Measure: Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement

Time: Week 52

Description: Endoscopic remission per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Remission

Time: Week 52

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Improvement in Participants with Endoscopic Improvement at Week 0

Time: Week 52

Description: Participants with a UC event that results in admission to the hospital.

Measure: Sub-Study 1: Percentage of Participants with Ulcerative Colitis (UC) Related Hospitalization

Time: Through Week 52

Description: Histologic remission per Geboes Score.

Measure: Sub-Study 1: Percentage of Participants with Histologic Remission

Time: Week 52

Description: Percentage of participants who reported no abdominal pain.

Measure: Sub-Study 1: Percentage of Participants who Reported No Abdominal Pain

Time: Week 52

Description: Percentage of participants who reported no bowel urgency.

Measure: Sub-Study 1: Percentage of Participants who Reported No Bowel Urgency

Time: Week 52

Description: Mucosal healing defined as endoscopic and histologic remission.

Measure: Sub-Study 1: Percentage of Participants with Mucosal Healing

Time: Week 52

Description: The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.

Measure: Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

Time: Baseline (Week 0) to Week 52

Description: Participants who underwent surgery related to UC.

Measure: Sub-Study 1: Percentage of Participants with Ulcerative Colitis (UC)-Related Surgeries

Time: Through Week 52

Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.

Measure: Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

Time: Week 0 to Week 52

Description: Percentage of participants who reported no nocturnal bowel movements.

Measure: Sub-Study 1: Percentage of Participants who Reported No Nocturnal Bowel Movements

Time: Week 52

Description: Percentage of participants who reported no tenesmus.

Measure: Sub-Study 1: Percentage of Participants who Reported No Tenesmus

Time: Week 52

Description: Change in number of fecal incontinence episodes per week.

Measure: Sub-Study 1: Change in Number of Fecal Incontinence Episodes per Week

Time: Baseline (Week 0) to Week 52

Description: Change in number of days per week with sleep interrupted due to UC symptoms.

Measure: Sub-Study 1: Change in Number of Days per Week with Sleep Interrupted due to UC Symptoms

Time: Baseline (Week 0) to Week 52

Description: The SF-36 is an indicator of overall health status.

Measure: Sub-Study 1: Change in 36-Item Short Form Health Status Survey (SF-36)

Time: Baseline (Week 0) to Week 52
8 A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.

NCT03398148
Conditions
  1. Ulcerative Colitis (UC)
Interventions
  1. Drug: risankizumab IV
  2. Drug: placebo for risankizumab
  3. Drug: risankizumab SC
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Clinical remission per adapted Mayo Score.

Measure: Sub-Study 1 and Sub-Study 2: Percentage of Participants with Clinical Remission per Adapted Mayo Score

Time: Week 12

Secondary Outcomes

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Improvement

Time: Week 12

Description: Clinical remission per Full Mayo Score.

Measure: Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Full Mayo Score in Participants with a Full Mayo Score of 6 to 12 at Baseline

Time: Week 12

Description: Clinical response per adapted Mayo Score.

Measure: Sub-Study 1: Percentage of Participants Achieving Clinical Response per Adapted Mayo Score

Time: Week 12

Description: Week 4

Measure: Sub-Study 1: Percentage of Participants Achieving Clinical Response per Partial Adapted Mayo Score

Time: Clinical response per Partial Adapted Mayo Score (without endoscopy).

Description: Endoscopic remission per endoscopy subscore.

Measure: Sub-Study 1: Percentage of Participants with Endoscopic Remission

Time: Week 12

Description: Participants with an event that results in admission to the hospital.

Measure: Sub-Study 1: Percentage of Participants with Hospitalization

Time: Through Week 12

Description: Mucosal healing defined as endoscopic and histologic remission.

Measure: Sub-Study 1: Percentage of Participants with Mucosal Healing

Time: Week 12

Description: The US-SQ is a patient questionnaire to assess severity of Crohn's symptoms.

Measure: Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)

Time: Baseline Through Week 12

Description: The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.

Measure: Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

Time: Baseline Through Week 12

Description: The SF-36 is an indicator of overall health status.

Measure: Sub-Study 1: Change in Short Form-36 (SF-36)

Time: Baseline Through Week 12

Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.

Measure: Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

Time: Baseline Through Week 12

Description: Participants who underwent surgery related to UC.

Measure: Sub-Study 1: Percentage of Participants with Ulcerative Colitis (UC)-related Surgeries

Time: Through 12 weeks

Description: Clinical remission per Full Mayo Score.

Measure: Sub-Study 2: Percentage of Participants Achieving Clinical Remission per Full Mayo Score in Participants with a Full Mayo Score of 6 to 12 at Baseline

Time: Week 12

Description: Clinical response per adapted Mayo Score.

Measure: Sub-Study 2: Percentage of Participants Achieving Clinical Response per Adapted Mayo Score

Time: Week 12

Description: Percentage of participants who reported no abdominal pain.

Measure: Sub-Study 2: Percentage of Participants who Reported No Abdominal Pain

Time: Week 12

Description: Percentage of participants who reported no bowel urgency.

Measure: Sub-Study 2: Percentage of Participants who Reported No Bowel Urgency

Time: Week 12

Description: Endoscopic remission per endoscopy subscore.

Measure: Sub-Study 2: Percentage of Participants with Endoscopic Remission

Time: Week 12

Description: Endoscopic improvement per endoscopy subscore.

Measure: Sub-Study 2: Percentage of Participants with Endoscopic Improvement

Time: Week 12

Description: The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.

Measure: Sub-Study 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)

Time: Baseline Through Week 12

Description: The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.

Measure: Sub-Study 2: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

Time: Baseline Through Week 12

Description: Percentage of participants with histological endoscopic improvement of the mucosa.

Measure: Sub-Study 2: Percentage of Participants with Histological Endoscopic Improvement of the Mucosa

Time: Week 12

Description: Percentage of participants who reported no nocturnal bowel movements.

Measure: Sub-Study 2: Percentage of Participants who Reported No Nocturnal Bowel Movements

Time: Week 12

Description: Percentage of participants who reported no tenesmus.

Measure: Sub-Study 2: Percentage of Participants who Reported No Tenesmus

Time: Week 12

Description: Change in number of fecal incontinence episodes per week.

Measure: Sub-Study 2: Change in Number of Fecal Incontinence Episodes per Week

Time: Baseline Through Week 12

Description: Change in number of days per week with sleep interrupted due to UC symptoms.

Measure: Sub-Study 2: Change in Number of Days per Week with Sleep Interrupted due to UC Symptoms

Time: Baseline Through Week 12

Description: Clinical response per partial adapted Mayo Score (without endoscopy), in participants with pancolitis at Baseline.

Measure: Sub-Study 2: Percentage of Participants Achieving Clinical Response per Partial Adapted Mayo Score in Participants with Pancolitis at Baseline

Time: Week 12

Description: Participants with an UC-related event that results in admission to the hospital.

Measure: Sub-Study 2: Percentage of Participants with Ulcerative Colitis (UC)-related Hospitalization

Time: Through Week 12

Description: The SF-36 is an indicator of overall health status.

Measure: Sub-Study 2: Change in Short Form-36 (SF-36)

Time: Baseline Through Week 12
9 A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study will evaluate the effect of repeated infusions of risankizumab on the pharmacokinetics of sensitive probe substrates of Cytochrome P450 (CYP) enzymes in participants with moderately to severely active UC or CD. Risankizumab is an investigational drug being developed to treat trial participants with inflammatory diseases such as UC and CD. The study is split into two periods. In Period 1, participants will receive single oral doses of CYP sensitive probes and in Period 2, participants will receive risankizumab followed by single oral doses of CYP sensitive probes. Around 20 adult participants with moderately to severely active CD or UC will be enrolled in the study across multiple sites worldwide. In Period 1, participants will receive oral doses of CYP sensitive probes on Day 1. In Period 2, participants will receive risankizumab by intravenous (IV) infusion on Days 1, 29 and 57 followed by oral CYP sensitive probes on Day 64. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.

NCT04254783
Conditions
  1. Ulcerative Colitis (UC)
  2. Crohn's Disease
Interventions
  1. Drug: Risankizumab
  2. Drug: Cytochrome P450 (CYP) Substrates
MeSH:Crohn Disease Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Crohn's disease Ulcerative colitis

Primary Outcomes

Description: Maximum observed plasma concentration (Cmax) of Midazolam

Measure: Maximum Observed Plasma Concentration (Cmax) of Midazolam

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Midazolam

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Midazolam

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Midazolam

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Midazolam

Measure: Terminal Phase Elimination Rate Constant (β) of Midazolam

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Midazolam

Measure: Terminal Phase Elimination Half-Life (t1/2) of Midazolam

Time: Up to 71 Days

Description: Maximum observed plasma concentration (Cmax) of Caffeine

Measure: Maximum Observed Plasma Concentration (Cmax) of Caffeine

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Caffeine

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Caffeine

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Caffeine

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Caffeine

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Caffeine

Measure: Terminal Phase Elimination Rate Constant (β) of Caffeine

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Caffeine

Measure: Terminal Phase Elimination Half-Life (t1/2) of Caffeine

Time: Up to 71 Days

Description: Maximum observed plasma concentration (Cmax) of Warfarin

Measure: Maximum Observed Plasma Concentration (Cmax) of Warfarin

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Warfarin

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Warfarin

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Warfarin

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Warfarin

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Warfarin

Measure: Terminal Phase Elimination Rate Constant (β) of Warfarin

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Warfarin

Measure: Terminal Phase Elimination Half-Life (t1/2) of Warfarin

Time: Up to 71 Days

Description: Maximum observed plasma concentration (Cmax) of Omeprazole

Measure: Maximum Observed Plasma Concentration (Cmax) of Omeprazole

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Omeprazole

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Omeprazole

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Omeprazole

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Omeprazole

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Omeprazole

Measure: Terminal Phase Elimination Rate Constant (β) of Omeprazole

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Omeprazole

Measure: Terminal Phase Elimination Half-Life (t1/2) of Omeprazole

Time: Up to 71 Days

Description: Maximum observed plasma concentration (Cmax) of Metoprolol

Measure: Maximum Observed Plasma Concentration (Cmax) of Metoprolol

Time: Up to 71 Days

Description: Time to maximum plasma concentration (Tmax) of Metoprolol

Measure: Time to Maximum Observed Plasma Concentration (Tmax) of Metoprolol

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration

Measure: Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Metoprolol

Time: Up to 71 Days

Description: Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity

Measure: AUC From Time 0 to Infinity (AUCinf) of Metoprolol

Time: Up to 71 Days

Description: Terminal phase elimination rate constant (β) for Metoprolol

Measure: Terminal Phase Elimination Rate Constant (β) of Metoprolol

Time: Up to 71 Days

Description: Terminal phase elimination half-life (t1/2) of Metoprolol

Measure: Terminal Phase Elimination Half-Life (t1/2) of Metoprolol

Time: Up to 71 Days
10 PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis: A Multi-centre Observational Case- Control Study

Whether the perceived changes in management of Acute Severe Ulcerative Colitis during the COVID pandemic are widespread, and whether they have any impact on patient outcomes

NCT04411784
Conditions
  1. Inflammatory Bowel Diseases
  2. COVID
MeSH:Colitis Colitis, Ulcerative Inflammatory Bowel Diseases
HPO:Colitis Inflammation of the large intestine Ulcerative colitis

Primary Outcomes

Description: The need for in-hospital colectomy or rescue therapy

Measure: Primary outcome measure: The need for in-hospital colectomy or rescue therapy

Time: 3 months

Secondary Outcomes

Description: Duration and type/route of steroid use

Measure: 2.1: Duration and type/route of steroid use

Time: 3 months

Description: 30 day colectomy free survival rates

Measure: 2.2: 30 day colectomy free survival rates

Time: 3 months

Description: Covid-19 infection rates

Measure: 2.3: Covid-19 infection rates

Time: 3 months

Description: Rate of Rescue therapy use

Measure: 2.4: Rate of Rescue therapy use

Time: 3 months

Description: Duration of hospital stay

Measure: 2.5: Duration of hospital stay

Time: 3 months

Description: Admission severity scoring

Measure: 2.6: Admission severity scoring

Time: 3 months

Description: Readmission rates

Measure: 2.7: Readmission rates

Time: 3 months
11 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Participants and Multiple Dose Study in Participants With Ulcerative Colitis to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-66525433

The purpose of this study is to evaluate safety and tolerability of JNJ 66525433 compared with placebo after administration of: 1) single ascending oral doses of JNJ 66525433 administered to healthy participants (Part 1), 2) multiple, ascending oral doses of JNJ 66525433, administered to healthy participants once daily over 14 consecutive days (Part 2), and 3) multiple oral doses of JNJ 66525433, administered once daily over 14 consecutive and once daily over 42 consecutive days in participants with ulcerative colitis (UC) (Part 3).

NCT04457960
Conditions
  1. Healthy
  2. Colitis, Ulcerative
Interventions
  1. Drug: JNJ-66525433
  2. Drug: Placebo
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Any AE occurring at or after the initial administration of study intervention through the day of last dose plus 30 days will be considered as TEAE.

Measure: Part 1, 2 and 3: Number of Participants with Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability

Time: Up to 224 Days

Description: Number of participants with vital sign abnormalities (temperature), pulse/heart rate, respiratory rate and blood pressure) will be reported.

Measure: Part 1, 2 and 3: Number of Participants with Vital Sign Abnormalities

Time: Up to 224 Days

Description: Number of participants with physical examination abnormalities will be reported.

Measure: Part 1, 2 and 3: Number of Participants with Physical Examination Abnormalities

Time: Up to 224 Days

Description: Number of participants with clinical laboratory abnormalities (serum chemistry, hematology and urinalysis) will be reported.

Measure: Part 1, 2 and 3: Number of Participants with Clinical Laboratory Abnormalities

Time: Up to 224 Days

Description: Number of participants with ECG abnormalities will be reported.

Measure: Part 1, 2 and 3: Number of Participants with Electrocardiogram (ECG) Abnormalities

Time: Up to 224 Days

Secondary Outcomes

Description: Plasma concentrations of JNJ-66525433 will be reported.

Measure: Part 1, 2 and 3: Plasma Concentrations of JNJ-66525433

Time: Up to 224 Days

Description: Plasma concentrations of JNJ-66525433 after fasted or fed dosing will be reported.

Measure: Part 1: Plasma Concentrations of JNJ-66525433 After Fasted or Fed Dosing

Time: Up to Day 14

Description: Mayo scoring system is used for assessment of ulcerative colitis activity. The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, physician's global assessment, and endoscopy findings) each ranges from 0 to 3. The Mayo score is calculated as the sum of these 4 subscores and can range between 0 and 12, where higher score indicates severe disease.

Measure: Part 3: Mayo Score

Time: Up to Day 84

Description: Partial Mayo score is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, and physician's global assessment) and ranges from 0 to 9 points. Higher score indicates severe disease.

Measure: Part 3: Partial Mayo Score

Time: Up to Day 70

Description: Endoscopy sub-score ranges from 0 to 3 where; 0 = normal or inactive disease; 1 = mild disease (erythema, decreased vascular pattern, mild friability); 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions); 3 = severe disease (spontaneous bleeding, ulceration).

Measure: Part 3: Endoscopic Subscore

Time: Up to Day 84

Description: IBDQ18 is a validated, 32-item, self-reported questionnaire for participants with inflammatory bowel disease (IBD) that will be used to evaluate the disease-specific health-related quality of life across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic functions (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

Measure: Part 3: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

Time: Days 1, 7, 14, 28, 43, 70 and 84

Description: Levels of mRNA knockdown will be reported to assess target engagement in biopsy tissue by dose level over time.

Measure: Part 2 and 3: Target Engagement of Messenger Ribonucleic Acid (mRNA) Levels

Time: Up to 182 Days

Description: Tissue biopsy concentrations of JNJ-66525433 will be reported.

Measure: Part 2 and 3: Tissue Biopsy JNJ-66525433 Concentrations

Time: Up to 182 Days
12 A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Ulcerative Colitis

The primary objective of this study is to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.

NCT04577794
Conditions
  1. Colitis, Ulcerative
Interventions
  1. Drug: GLPG3970
  2. Drug: Placebo
MeSH:Colitis Colitis, Ulcerative Ulcer
HPO:Colitis Ulcerative colitis

Primary Outcomes

Description: Mayo score is an instrument designed to measure disease activity of UC. Total Mayo score consists of 4 sub-scores: stool frequency, rectal bleeding, flexible sigmoidoscopy and physician's global assessment, each graded from 0 to 3. These scores are summed to give a total score range of 0 to 12, with higher total scores indicating more severe disease.

Measure: Change From Baseline in Total Mayo Clinical Score (MCS) at Week 6

Time: Baseline and Week 6

Secondary Outcomes

Measure: Incidence of Treatment-emergent Adverse Events (TEAEs) by Severity

Time: Screening up to Follow-up (Week 13)

Measure: Observed Plasma Trough Concentration (Ctrough) of GLPG3970

Time: Predose (within 30 minutes prior to dosing) on Days 15, 29 and 43

HPO Nodes


HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials

Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook